PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Br J Haematol. Author manuscript; available in PMC 2009 September 22.
Published in final edited form as:
PMCID: PMC2748973
NIHMSID: NIHMS69321

Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines

Summary

The establishment of clinically relevant human myeloma cell lines is central for our understanding of myeloma pathogenesis and development of novel therapies for the disease. Unfortunately, most available lines were generated from extramedullary sites, harbored multiple genetic abnormalities and categorized as non-hyperdiploid. In contrast, hyperdiploid myeloma cell lines, which represent more than 50% of patients, are rare. We established procedures for establishment of stroma-dependent myeloma lines by passaging primary myeloma cells, in severe combined immunodeficient-human (SCID-hu) or SCID-rab mice followed by maintenance in co-culture with stromal cells. We described the establishment and characterization of two hyperdiploid (LD and CF) and two non-hyperdiploid (JB and BN) cell lines. Using our animal models, we also established bortezomib-sensitive and -resistant BN lines. These cell lines were cellularly, phenotypically and molecularly characterized using flow cytometry immunophenotyping, DNA content, G-band and multicolor spectral karyotyping (SKY) and global gene expression profiling. All four cell lines were infected with lentiviral-expressing luciferase for detection of tumour cells at high sensitivity level and for monitoring myeloma growth in co-cultures and in vivo by live animal imaging. These myeloma cell lines and the procedures used for their establishment provide essential tools for studying myeloma biology and therapy.

Keywords: hyperdiploid myeloma, myeloma cell lines, bioluminescent imaging

Recently, global gene expression profiling and the sensitive molecular techniques used to detect genetic abnormalities revealed that myeloma is a heterogeneous disease associated with multiple chromosomal abnormities (Hallek et al, 1998; Fonseca et al, 2004; Bergsagel et al, 2005; Bergsagel & Kuehl, 2005) and highly deviated molecular profiles (Zhan et al, 2002, 2006). Over the past two decades, many human myeloma cell lines have been established that have significantly contributed to our understanding of various aspects of myeloma pathogenesis, including the identification of common chromosomal translocations and genetic aberrations, mechanisms of drug resistance, and major signalling pathways associated with responses to specific growth factors (Bataille et al, 1989; Mazars et al, 1992; Abbaszadegan et al, 1996; Billadeau et al, 1997; Akiyama et al, 2002; Croonquist et al, 2003; Hazlehurst et al, 2003; Hideshima et al, 2003; Mitsiades et al, 2003; Tassone et al, 2005). Nevertheless, most of these cell lines, including stroma- and cytokine-dependent myeloma lines (Chesi et al, 1997; Bergsagel & Kuehl, 2001; De Vos et al, 2001; Verdelli et al, 2005), were derived from extramedullary sites of patients at the end stage of myeloma, are highly proliferative, and grow aggressively and independently of the bone marrow microenvironment in vitro and in animal models; their growth patterns do not reflect those seen clinically, where low-proliferating tumour cells restrictively reside in the haematopoietic marrow and are protected from spontaneous and drug-induced apoptosis. Furthermore, the majority of these lines are cytogenetically classified as non-hyperdiploid myeloma, which represents patients with poor prognosis (Smadja et al, 1998, 2001; bes-Marun et al, 2003; Fonseca et al, 2003).

While previously established cell lines have been useful, at this stage of myeloma research there is a need for clinically relevant hyperdiploid myeloma cell lines. Such lines will help to understand the key aspects of myeloma biology, including the myeloma ‘stem cell’ and its proliferative compartment, transformation from benign to active disease stages, and development of drug resistance; these lines will also facilitate validation of novel targeted therapies for myeloma and its related bone disease, based on interactions between myeloma cells and their microenvironment.

To date, the severe combined immunodeficient-human (SCID-hu) and SCID-rab murine models are the only systems in which primary myeloma cells taken from patients with medullary myeloma can potentially undergo sequential passages in vivo and ex vivo and become low-proliferating, bone marrow-dependent myeloma lines. Reproducible engraftment of primary human myeloma cells in SCID-hu (Yaccoby et al, 1998) and SCID-rab (Yata & Yaccoby, 2004) mice has fundamentally contributed to our understanding of crucial aspects of the clonogenic potential of mature myeloma plasma cells (Yaccoby & Epstein, 1999; Yata & Yaccoby, 2004) and the role of bone marrow microenvironment in disease progression (Yaccoby et al, 2002a,b, 2006, 2007). In these systems, myeloma cells from patients at various disease stages are successfully engrafted, grow slowly but exclusively in the implanted bone, and produce typical disease manifestations of myeloma. These models also enabled us to generate clinically relevant myeloma cell lines from primary patient samples of intramedullary disease. Here, we describe the establishment and characterization of four myeloma cell lines.

Materials and methods

Myeloma cell analyses

Multiple myeloma (MM) cells were obtained from heparinized bone marrow (BM) aspirates from four patients with active myeloma during scheduled clinic visits. Signed Institutional Review Board – approved informed consent forms are kept on record. Pertinent patient information is provided in Table I. The BM samples were separated by density centrifugation using Ficoll-Paque (specific gravity, 1.077 g/ml; Amersham Biosciences Corp., Piscataway, NJ, USA). Myeloma cells recovered from tumour-engrafted mice were analysed for the presence of Epstein–Barr virus (EBV) sequences and transcripts by polymerase chain reaction (PCR) and reverse transcription (RT)-PCR (Miyashita et al, 1995). All tested samples were negative. Flow cytometry immunophenotypic characterization of myeloma cells was performed using CD45, CD38, CD138 and CD56 monoclonal antibodies (Becton Dickenson, San Jose, CA, USA). Cytofluorimetric analysis of DNA content, conventional karyotyping and multicolor spectral karyotyping (SKY) were performed as previously described (Latreille et al, 1980; Sawyer et al, 2001). Gene expression profiling on CD138-selected myeloma cells was performed with the Affymetrix U133Plus2.0 microarray platform (Santa Clara, CA, USA) using methods previously described (Zhan et al, 2002, 2006).

Table I
Characteristics of cell lines and patients.

Myelomatous SCID-hu and SCID-rab mice

Both SCID-hu and SCID-rab mice were constructed as previously described (Yaccoby et al, 1998; Yata & Yaccoby, 2004). Myeloma cells (0.1–5 × 106 cells) in 50–100 μl of phosphate-buffered saline (PBS) were injected directly into the implanted bone in SCID-hu or SCID-rab mice. Mice were periodically bled from the tail vein and changes in levels of circulating human immunoglobulin (hIg) of the M-protein isotype were used as an indicator of MM growth. For testing the effect of bortezomib (Millennium Pharmaceuticals, Inc., Boston, MA, USA), myelomatous hosts were treated subcutaneously with saline or bortezomib (0.5 mg/kg body weight twice a week) (LeBlanc et al, 2002) for 5 weeks.

Determination of human hIg levels

Levels of human κ and λ light chains were determined by enzyme-linked immunosorbent assay (ELISA) as described (Yaccoby et al, 1998; Yaccoby & Epstein, 1999). At the end of each experiment, all samples were analysed in the same assay in order to preclude inter-assay variability.

Myeloma-stromal cells co-cultures

Mesenchymal stem cells (hereinafter, stromal cells) were prepared as previously described (Yaccoby, 2005; Ge et al, 2006). Briefly, bone marrow mononucleated cells (2 × 106 cells/ml) from human fetal bone fragments (Advanced Bioscience Resources, Alameda, CA, USA) were cultured in low-glucose Dulbecco's modified Eagle's medium (DMEM-LG) supplemented with 10% fetal bovine serum (FBS) and antibiotics. One-half of the medium was replaced every 4–6 d, and adherent cells were allowed to reach 80% confluency before they were subcultured with trypsin–EDTA. The adherent stromal cells expressed CD166, but not CD45 or CD34, and were capable of differentiating into mesenchymal lineage, such as osteoblasts and adipocytes (Yaccoby et al, 2006). Myeloma cell lines were co-cultured with stromal cells in RPMI-1640 media supplemented with 10% FBS and antibiotics and one-half of the medium was replaced every 5–7 d. For passaging myeloma cells to new cultures, non-adherent myeloma cells were collected from co-cultures, spun to remove excessive media and then seeded in flasks-containing stromal cells.

Lentiviral vector, myeloma cell infection and live animal imaging

We constructed a lentiviral vector (pLenti6/V5/EGFPLuc) expressing both enhanced green fluorescent protein (EGFP) and luciferase. DNA sequences of EGFPLuc encodes a fusion of EGFP and luciferase from the firefly Photinus pyralis was cloned by PCR from the pEGFPLuc vector (Clontech, Mountain View, CA, USA) and inserted into pLenti6/V5-D-TOPO vector using pLenti/V5 Directional TOPO Cloning Kit (Invitrogen, Carlsbad, CA, USA). Lentiviral particles were generated by cotransfecting the expression vector pLenti6/V5/EGFPLuc and ViraPower Packaging Mix into 293FT cells according to the Invitrogen's ViraPower Lentiviral Expression Systems protocol. Myeloma cells were plated in 24-well plate (100 000 cells/well) and transduced by adding the lentiviral particles to cell suspensions at a multiplicity of infection (MOI) of 2 for 24–48 h. The medium containing lentivirus was removed, replaced with fresh RPMI-1640 medium supplemented with 10% FBS and antibiotics and infected cells were allowed to grow in co-culture with stromal cells (Yaccoby et al, 2006). EGFP/luciferase-expressing myeloma cells were then sorted by fluorescent-activated cell sorting (FACS) based on EGFP expression and further expanded in co-culture with stromal cells prior to their exploitation in vivo and in vitro. For live imaging, mice were anaesthetized with ketamine plus xylazine and injected intraperitoneally with d-luciferin firefly (150 mg/kg; Xenogen, Corp. Alameda, CA, USA). Luciferase activity was detected using IVIS 200 imaging system (Xenogen).

In vitro luciferase assay

Stromal cells were cultured in 96-well microplates with white clear bottom (Thermo Labsystems, Waltham, MA, USA). Indicated numbers of myeloma cells were co-cultured with MSCs in 100 μl of RPMI 1640 media supplemented with 10% FBS and antibiotics for indicated periods of time. In some experiments co-cultures were treated with various doses of bortezomib, dexamethasone and melphalan for 72 h. At the end of the incubation period, d-luciferin K+ salt was added to the cultures (150 μg/ml) and luciferase activity was determined after 5 min using LumiCount (PerkinElmer Life and Analytical Sciences, Shelton, CT, USA).

Results

Establishment of myeloma cells lines

The growth of primary myeloma cells in SCID-hu and SCID-rab mice have been intensively characterized (Yaccoby et al, 1998; Yaccoby & Epstein, 1999; Yaccoby et al, 2002a,b; Yata & Yaccoby, 2004; Yaccoby et al, 2007). Using more than 300 samples, we have found that myeloma cells from >80% of patients successfully engrafted and grew similarly in both models. In the majority of cases, myeloma growth was restricted to the implanted bones; however, in approximately 5–10% of cases, myeloma growth was also apparent on the outer surface of the implanted bone. This growth pattern is expected when myeloma cells are taken from patients with extramedullary disease (e.g. plasma cell leukaemia, plasmacytoma), but we also observed this growth pattern from cells of some tumours obtained from bone marrow of patients with medullary myeloma. Those cases provided the materials for establishing four clinically relevant myeloma cell lines. A large amount of these tumour cells were recovered from the implanted bone and passaged to freshly prepared SCID-hu or SCID-rab mice.

Cellular and molecular characterization of myeloma cell lines

Following passages in vivo our cell lines retained their dependence on bone marrow in vitro; they did not grow independently in culture but grew and maintained in co-culture with stromal cells as stroma-dependent myeloma lines. These cells also retained the slow growth characteristics of primary myeloma; in contrast to typical stroma independent lines whose doubling time is approximately 1–2 d, the doubling time for lines BN, JB and CF was approximately 4–6 d, while that of LD was approximately 10 d. Cell–cell contact with stromal cells was required for their growth, and single factors [e.g. interleukin (IL)-6 or insulin-like growth factor-1] were insufficient to stimulate their long-term growth in vitro (data not shown). When cells from our lines were injected back into implanted bones of newly constructed SCID-hu or SCID-rab mice, they grew and produced typical myeloma manifestations (e.g. bone disease) (Yaccoby et al, 2002b, 2007); however, these cells did not grow after intraperitoneal (i.p.), subcutaneous (s.c.), or intravenous (i.v.) injection into SCID mice.

All the four established cell lines were EBV-negative and produced the same M isotype as the original patients' cells; these cell lines expressed high levels of CD38 and CD138 and varying levels of CD45 and CD56 (Fig 1). Flow cytometric analysis of DNA content (Latreille et al, 1980) revealed that LD and CF lines were hyperdiploid and JB and BN were pseudodiploid (Table I).

Fig 1
Immunophenotypic analysis of four myeloma cell lines. LD, CF, JB and BN cells were stained with CD45/CD38 and CD138/CD45 and analysed by flow cytometry. Note the high expression of CD38 and CD138, and various expression level of CD45 and CD56 by these ...

Conventional G-band karyotype designations of the original patient's MM cells and the corresponding cell line designations indicated that the cell lines originated from the patient's tumour clone (Table II). Combined G-banding and SKY analysis (Sawyer et al, 2001) were used to characterize the multiple complex cytogenetic abnormalities in each of these lines (Fig 2). The two hyperdiploid, LD and CF lines were characterized by multiple trisomies; LD cells showed trisomies for chromosomes 5, 6, 8, 9 and 20, and structural aberrations involving extra copies of 1q translocated to 8(p23)×2. The CF cell line showed at least partial trisomies for chromosomes 1, 3, 5, 7, 9, 11, 18 and 19, and structural aberrations including dup(1)(q12~23)×2. The JB and BN cell lines were both hypodiploid and were monosomic for chromosome 13. The JB cells showed structural aberrations including extra segments of 1q translocated to 2(p23) and 15(pter). The BN cell line showed two whole-arm translocations involving 1q, one involving 1q and 19p, and the other involving 1q and 17q.

Fig 2
Representative G-band (top panel) and spectral karyotyping (SKY; bottom panel) karyotypes demonstrating different translocations and chromosome aneuploidies in LD (A), CF (B), JB (C) and BN (D) myeloma cell lines. The most common structural aberrations ...
Table II
G-band karyotype designations of patient's tumour specimens and corresponding G-band cell line designations.

To further characterize our lines at the molecular level, global gene expression profiling was performed and listed genes known to be associated with myeloma pathogenesis (Table III). Expression levels of these genes in each of the lines were compared with gene expression levels of newly diagnosed myeloma patients included in the TTII clinical trial at our institute (Zhan et al, 2006). Global gene expression profiling has been successfully used to predict major gene translocations involving the immunoglobulin heavy chain (IgH) locus and chromosomal deletion based on spiked genes (Zhan et al, 2002; Bergsagel et al, 2005; Zhan et al, 2006; Chng et al, 2007). According to the spiked expression of WHSC1 (also known as MMSET), FGFR3 and CCND2 in JB and BN cells belong to the MMSET subgroup (Zhan et al, 2006) which harbors the t(4;14) translocation (Zhan et al, 2002; Bergsagel et al, 2005). In contrast, LD and CF cells, which appear to have no IgH translocations expressed high level of DKK1, a Wnt signalling inhibitor that has been closely associated with hyperdiploid myeloma (Table III) (Tian et al, 2003; Zhan et al, 2006).

Table III
Microarray signal of selected genes associated with myeloma pathogenesis in four myeloma cell lines.

Exploitation of myeloma cells for studying therapeutic approaches

To improve the use of our cell lines for studying myeloma biology and therapy in vivo and in vitro, we infected these cells with lentiviral-expressing luciferase. As shown in Fig 3, the growth of myeloma cells in SCID-hu mice, as determined by live animal imaging highly, correlated with hIg levels in mice sera. Live animal imaging also confirmed our previous observation demonstrating that myeloma cell growth is restricted to the implanted bone. In additional studies, hosts engrafted with CF and BN cells and, upon establishment of myeloma growth, were treated with bortezomib for 5 weeks. As demonstrated in Fig 3D, BN but not CF cells responded to bortezomib, and BN-bearing mice showed no detection of luciferase at the given sensitivity level after treatment.

Fig 3
Bioluminescent imaging of myeloma growth in vivo. Our myeloma cell lines were infected with luciferase-containing lentivirus as a marker for tracing myeloma growth in live SCID-hu and SCID-rab mice. Luciferase activity was detected using IVIS 200 imaging ...

To further explore the clinical application of these cell lines, we established bortezomib-resistant and -sensitive BN cells by exposing SCID-rab mice bearing BN cells to bortezomib (n = 3). A representative experiment of one host is demonstrated in Fig 4A. Following 4 weeks of bortezomib treatment, mice achieved complete response, and treatment was stopped. Mice remained in remission for 14 weeks but then relapsed, and treatment was resumed (Fig 4A). At this point, mice did not respond to treatment, and myeloma cells recovered from one of these mice were also resistant to bortezomib following passages into newly constructed SCID-rab mice (Fig 4B) and in vitro (Fig 4C). We also compared gene expression profiles of bortezomib-resistant and -sensitive BN cells (Table IV). While some identified genes are directly associated with drug resistance (e.g. ABCB1, BCL2), other genes may be used as prognosis markers (e.g. CD9) associated with response to bortezomib.

Fig 4
Establishment of a bortezomib-resistant myeloma cell line in vivo. SCID-hu mice engrafted with BN cells were treated with bortezomib (BOR) or left untreated. Note that hosts initially responded to BOR; however, when myeloma recurred, BN cells were resistant ...
Table IV
Partial list of genes differentially expressed between bortezomib-resistant and -sensitive BN cells.

Using our luciferase-expressing myeloma cell lines we established a growth assay for myeloma cells in co-culture with stromal cells. Myeloma cells often firmly adhere to stroma cells, preventing recovery of cells. We initially correlated between the number of myeloma cells seeded on stromal cells and level of luciferase activity by these cells. There was high correlation (r = 0.997) between myeloma cell number and luciferase activity in the co-cultures (Fig 5). This assay was exploited to study the effect of bortezomib, melphalan and dexamethasone on growth of BN myeloma cells (20 000 cells/well) in co-culture with the supporting stromal cells. Whereas bortezomib and melphalan inhibited BN cell growth in a dose-dependent manner (50% inhibitory concentration (IC50) c. 5 nmol/l and c. 0.9 μmol/l for bortezomib and melphalan respectively), BN cells responded to dexamethasone only in doses greater than 200 μmol/l (Fig 5).

Fig 5
Establishment of in vitro growth assay of myeloma cells in co-culture with stromal cells. (A) Luciferase (Luc) activity was highly correlated with number of tumour cells in co-cultures (r = 0.997). (B) A study demonstrating the effect of various doses ...

Discussion

Myeloma has been classified into two broad genetic, hyperdiploid and non-hyperdiploid subtypes (Fonseca et al, 2004; Bergsagel & Kuehl, 2005). Hyperdiploid myeloma cells are characterized by an increased number of chromosomes (48–74) often reflecting multiple trisomies, lower prevalence of primary translocations involving the IgH locus at 14q32 and high dependency on the BM microenvironment. Patients with non-hyperdiploid myeloma are associated with the presence of primary IgH translocations such as t(4;14), t(11;14) and t(14;16) (Fonseca et al, 2003; Bergsagel et al, 2005). Progress in understanding the biology of hyperdiploid myeloma has been hampered mainly due to lack of appropriate available cell lines (Fonseca et al, 2004). This report describes the establishment of LD, CF, JB and BN human myeloma cell lines, two of which (LD and CF) were categorized as hyperdiploid myeloma. G-banding karyotyping analysis showed that the cell lines originated from the corresponding patient's clone. Although hyperdiploid myeloma patients are generally thought to have better prognosis than those with non-hyperdiploid myeloma, a subset of hyperdiploid myeloma with poor outcome has been recently identified by global gene expression profiling (Zhan et al, 2006; Chng et al, 2007). The molecular classification of the two established hyperdiploid lines in the proliferation group indicated that they originated from high-risk myeloma (Zhan et al, 2006). Using our animal models, we also developed in vivo procedures to establish drug-resistant variants and demonstrated the development of bortezomib-sensitive and -resistant BN cells.

Our myeloma cell lines retained slow growth as stroma-dependent cells in vitro and disseminated restrictively in the implanted human or rabbit bones in SCID-hu and SCID-rab mice respectively. These cells thus better reflect the growth of primary myeloma in the bone marrow. The two hyperdiploid myeloma cell lines, particularly LD cells, have lower growth rate in vitro and in vivo than the two non-hyperdiploid lines, and thus are favoured for studying the interaction of myeloma cells with the bone marrow microenvironment.

Using lentiviral-expressing luciferase we developed a highly sensitive assay to monitor tumour growth in co-culture of our myeloma cell lines with stromal cells and in SCID-hu/SCID-rab mice. Fewer than 500 myeloma cells could reliably be detected in vitro and 5000 cells in the implanted bone of SCID-hu/SCID-rab mice. The luciferase-expressing myeloma cells have been successfully exploited to test the effect of various drugs on myeloma cell growth in co-culture and in vivo.

Taken together, we have established two hyperdiploid and two non-hyperdiploid human stroma-depended myeloma lines. Their growth rate and patterns reflect primary myeloma and thus are biologically and clinically relevant. These cells have been exploited to monitor tumour growth using luciferase-expressing myeloma cells in ongoing co-cultures and in live animals, to study myeloma therapy and development of drug-resistance. These myeloma cell lines and the procedures used for their establishment provide essential tools for studying myeloma biology and therapy.

Acknowledgments

This study was supported by a grant from the National Cancer Institute (CA-93897) and Senior and Translational grants from the Multiple Myeloma Research Foundation (S.Y.).

References

  • Abbaszadegan MR, Foley NE, Gleason-Guzman MC, Dalton WS. Resistance to the chemosensitizer verapamil in a multi-drug-resistant (MDR) human multiple myeloma cell line. International Journal of Cancer. 1996;66:506–514. [PubMed]
  • Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, MItsiades N, Chauhan D, Richardson P, Munshi NC, Anderson KC. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Research. 2002;62:3876–3882. [PubMed]
  • Bataille R, Klein B, Jourdan M, Rossi JF, Durie BG. Spontaneous secretion of tumor necrosis factor-beta by human myeloma cell lines. Cancer. 1989;63:877–880. [PubMed]
  • Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene. 2001;20:5611–5622. [PubMed]
  • Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. Journal of Clinical Oncology. 2005;23:6333–6338. [PubMed]
  • Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J., Jr Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106:296–303. [PubMed]
  • bes-Marun CS, Dewald GW, Bryant S, Picken E, Santana-Davila R, Gonzalez-Paz N, Winkler JM, Kyle RA, Gertz MA, Witzig TE, Dispenzieri A, Lacy MQ, Rajkumar SV, Lust JA, Greipp PR, Fonseca R. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia. 2003;17:427–436. [PubMed]
  • Billadeau D, Liu P, Jelinek D, Shah N, LeBien TW, Van Ness B. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6. Cancer Research. 1997;57:2268–2275. [PubMed]
  • Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM, Bergsagel PL. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genetics. 1997;16:260–264. [PMC free article] [PubMed]
  • Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K, Chung TH, Kim S, Mulligan G, Bryant B, Carpten J, Gertz M, Rajkumar SV, Lacy M, Dispenzieri A, Kyle R, Greipp P, Bergsagel PL, Fonseca R. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Research. 2007;67:2982–2989. [PubMed]
  • Croonquist PA, Linden MA, Zhao F, Van Ness BG. Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells. Blood. 2003;102:2581–2592. [PubMed]
  • De Vos J, Couderc G, Tarte K, Jourdan M, Requirand G, Delteil MC, Rossi JF, Mechti N, Klein B. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood. 2001;98:771–780. [PubMed]
  • Fonseca R, bes-Marun CS, Picken EB, Dewald GW, Bryant SC, Winkler JM, Blood E, Oken MM, Santana-Davila R, Gonzalez-Paz N, Kyle RA, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003;102:2562–2567. [PubMed]
  • Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, Kuehl WM, Hernandez JM, Minvielle S, Pilarski LM, Shaughnessy JD, Jr, Stewart AK, Avet-Loiseau H. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Research. 2004;64:1546–1558. [PubMed]
  • Ge Y, Zhan F, Barlogie B, Epstein J, Shaughnessy J, Yaccoby Y. Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival. British Journal of Haematology. 2006;133:83–92. [PubMed]
  • Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91:3–21. [PMC free article] [PubMed]
  • Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH, Saporta S, Boulware D, Moscinski L, Alsina M, Dalton WS. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Research. 2003;63:7900–7906. [PubMed]
  • Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C, Podar K, Munshi NC, Richardson PG, Anderson KC. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene. 2003;22:8386–8393. [PubMed]
  • Latreille J, Barlogie B, Dosik G, Johnston DA, Drewinko B, Alexanian R. Cellular DNA content as a marker of human multiple myeloma. Blood. 1980;55:403–408. [PubMed]
  • LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC, Anderson KC. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Research. 2002;62:4996–5000. [PubMed]
  • Mazars GR, Portier M, Zhang XG, Jourdan M, Bataille R, Theillet C, Klein B. Mutations of the p53 gene in human myeloma cell lines. Oncogene. 1992;7:1015–1018. [PubMed]
  • Mitsiades CS, Mitsiades NS, Bronson RT, Chauhan D, Munshi N, Treon SP, Maxwell CA, Pilarski L, Hideshima T, Hoffman RM, Anderson KC. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Research. 2003;63:6689–6696. [PubMed]
  • Miyashita EM, Yang B, Lam KM, Crawford DH, Thorley-Lawson DA. A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell. 1995;80:593–601. [PubMed]
  • Sawyer JR, Lukacs JL, Thomas EL, Swanson CM, Goosen LS, Sammartino G, Gilliland JC, Munshi NC, Tricot G, Shaughnessy JD, Jr, Barlogie B. Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. British Journal of Haematology. 2001;112:167–174. [PubMed]
  • Smadja NV, Fruchart C, Isnard F, Louvet C, Dutel JL, Cheron N, Grange MJ, Monconduit M, Bastard C. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia. 1998;12:960–969. [PubMed]
  • Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001;98:2229–2238. [PubMed]
  • Tassone P, Neri P, Carrasco DR, Burger R, Goldmacher VS, Fram R, Munshi V, Shammas MA, Catley L, Jacob GS, Venuta S, Anderson KC, Munshi NC. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood. 2005;106:713–716. [PubMed]
  • Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD., Jr The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. New England Journal of Medicine. 2003;349:2483–2494. [PubMed]
  • Verdelli D, Mattioli M, Fabris S, Nobili L, Intini D, Guerneri S, Todoerti K, Zanella A, Deliliers GL, Lombardi L, Neri A. Molecular and biological characterization of three novel interleukin-6-dependent human myeloma cell lines. Haematologica. 2005;90:1541–1548. [PubMed]
  • Yaccoby S. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clinical Cancer Research. 2005;11:7599–7606. [PMC free article] [PubMed]
  • Yaccoby S, Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood. 1999;94:3576–3582. [PubMed]
  • Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood. 1998;92:2908–2913. [PubMed]
  • Yaccoby S, Johnson CL, Mahaffey SC, Wezeman MJ, Barlogie B, Epstein J. Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood. 2002a;100:4162–4168. [PubMed]
  • Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. British Journal of Haematology. 2002b;116:278–290. [PubMed]
  • Yaccoby S, Wezeman MJ, Zangari M, Walker R, Cottler-Fox M, Gaddy D, Ling W, Saha R, Barlogie B, Tricot G, Epstein J. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica. 2006;91:192–199. [PMC free article] [PubMed]
  • Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD., Jr Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007;109:2106–2111. [PubMed]
  • Yata K, Yaccoby S. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia. 2004;18:1891–1897. [PubMed]
  • Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B, Shaughnessy J., Jr Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99:1745–1757. [PubMed]
  • Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD., Jr The molecular classification of multiple myeloma. Blood. 2006;108:2020–2028. [PubMed]